Clinical trials: Immunosuppression For Disease
Immunosuppression, Cancer
Clinical Trial for Assessment of Anti-SARS-CoV-2 Serum for Early Treatment of COVID-19 Cases
Phase I/II Randomized Clinical Trial to evaluate the safety, pharmacokinetic and efficacy of Anti-SARS-CoV-2 hyperimmune serum. The study will include patients at early stage of COVID-19 with increased risk for severe disease due…
- Conditions
- Immunosuppression, Cancer, COVID-19, Other Complication of Kidney Transplant
- Trial name
- SOROCOV (NCT04834089)
- Testing
- AntiSARS-CoV-2 Serum
- Where
- 2 sites in Brazil
- Volunteers
- 618 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Immunosuppression For Disease
Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020
The purpose of this study is to assess the pharmacokinetics (PK), metabolism, routes and extent of elimination, as well as safety and tolerability of a single oral solution dose of [14C] Bristol-Myers Squibb (BMS)-986020 in…
- Trial name
- NCT02068053
- Testing
- [14C] BMS-986020
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Immunosuppression For Disease
Drug Interaction Study With Rosuvastatin
The purpose of this study is to evaluate the effect of concomitant administration of BMS-986020 on the single dose Pharmacokinetics (PK) of Rosuvastatin in healthy subjects.
- Trial name
- NCT02101125
- Testing
- BMS-986020, Rosuvastatin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Tumor Immunity, Immunosuppression
RFA Plus Carrizumab vs Carrizumab Alone for HCC
The study aims to find whether patients with advanced HCC can get more benefits from RFA +PD-1 immunosuppressant (carrizumab) compared with carrizumab alone, considering with the result of PFS.
- Conditions
- Tumor Immunity, Immunosuppression, Radiofrequency Ablation
- Trial name
- NCT04150744
- Testing
- radiofrequency ablation
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Actinic Keratoses
Safety and Efficacy of Imiquimod Applied in Dose-Cycle for Actinic Keratoses
It is believed that imiquimod 5% cream has the potential to be an effective treatment for actinic keratoses. The purpose of this study is to evaluate the duration of the effect of topical imiquimod 5% topical cream for the…
- Trial name
- NCT00175643
- Testing
- imiquimod
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of British Columbia